These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37750202)

  • 21. Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer in the United States.
    Criss SD; Mooradian MJ; Watson TR; Gainor JF; Reynolds KL; Kong CY
    JAMA Netw Open; 2019 Sep; 2(9):e1911952. PubMed ID: 31553470
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.
    Shu CA; Gainor JF; Awad MM; Chiuzan C; Grigg CM; Pabani A; Garofano RF; Stoopler MB; Cheng SK; White A; Lanuti M; D'Ovidio F; Bacchetta M; Sonett JR; Saqi A; Rizvi NA
    Lancet Oncol; 2020 Jun; 21(6):786-795. PubMed ID: 32386568
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Atezolizumab-associated myositis in a patient with unresectable hepatocellular carcinoma.
    Baigi T; Brown EN; De La Torre RM; Abu-Shahin FI
    J Oncol Pharm Pract; 2023 Oct; 29(7):1757-1761. PubMed ID: 37282559
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancer: A case report and literature review.
    Chen JH; Lee KY; Hu CJ; Chung CC
    Medicine (Baltimore); 2017 Dec; 96(50):e9262. PubMed ID: 29390370
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of atezolizumab, durvalumab, pembrolizumab, and nivolumab as first-line treatment in patients with extensive-stage small cell lung cancer: A systematic review and network meta-analysis.
    Chen J; Wang J; Xu H
    Medicine (Baltimore); 2021 Apr; 100(15):e25180. PubMed ID: 33847617
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Atezolizumab-induced Sclerosing Cholangitis in a patient with lung cancer: A case report.
    Nabeshima S; Yamasaki M; Matsumoto N; Takaki S; Nishi Y; Kawamoto K; Taniwaki M; Ohashi N; Hattori N
    Cancer Treat Res Commun; 2021; 26():100270. PubMed ID: 33338849
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
    West H; McCleod M; Hussein M; Morabito A; Rittmeyer A; Conter HJ; Kopp HG; Daniel D; McCune S; Mekhail T; Zer A; Reinmuth N; Sadiq A; Sandler A; Lin W; Ochi Lohmann T; Archer V; Wang L; Kowanetz M; Cappuzzo F
    Lancet Oncol; 2019 Jul; 20(7):924-937. PubMed ID: 31122901
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune Checkpoint Inhibitor-Induced Myositis: a Case Report and Literature Review.
    Kadota H; Gono T; Shirai Y; Okazaki Y; Takeno M; Kuwana M
    Curr Rheumatol Rep; 2019 Feb; 21(4):10. PubMed ID: 30790071
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fulminant myocarditis during postoperative adjuvant chemotherapy for lung cancer with atezolizumab: a case report.
    Tokunaga T; Aoki M; Maruyama K; Nonaka Y; Kariatsumari K; Sakasegawa K; Ueda K
    J Med Case Rep; 2024 Mar; 18(1):162. PubMed ID: 38491548
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nivolumab and Ipilimumab-induced myositis and myocarditis mimicking a myasthenia gravis presentation.
    Valenti-Azcarate R; Esparragosa Vazquez I; Toledano Illan C; Idoate Gastearena MA; Gállego Pérez-Larraya J
    Neuromuscul Disord; 2020 Jan; 30(1):67-69. PubMed ID: 31839404
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nintedanib allows retreatment with atezolizumab of combined non-small cell lung cancer/idiopathic pulmonary fibrosis after atezolizumab-induced pneumonitis: a case report.
    Yamakawa H; Oba T; Ohta H; Tsukahara Y; Kida G; Tsumiyama E; Nishizawa T; Kawabe R; Sato S; Akasaka K; Amano M; Kuwano K; Matsushima H
    BMC Pulm Med; 2019 Aug; 19(1):156. PubMed ID: 31438923
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Successful Treatment of Non-small-cell Lung Cancer with Atezolizumab Following Tubulointerstitial Nephritis Due to Pembrolizumab.
    Taki T; Oda N; Fujioka Y; Mitani R; Tokura T; Takata I; Oshiro Y; Takigawa N
    Intern Med; 2020 Jul; 59(13):1639-1642. PubMed ID: 32269191
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [A case of myasthenia gravis and myositis induced by pembrolizumab].
    Noda T; Kageyama H; Miura M; Tamura T; Ito H
    Rinsho Shinkeigaku; 2019 Aug; 59(8):502-508. PubMed ID: 31341124
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune checkpoint inhibitors (ICIs)-related ocular myositis.
    Garibaldi M; Calabrò F; Merlonghi G; Pugliese S; Ceccanti M; Cristiano L; Tartaglione T; Petrucci A
    Neuromuscul Disord; 2020 May; 30(5):420-423. PubMed ID: 32387281
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atezolizumab and bevacizumab-induced encephalitis in advanced hepatocellular carcinoma: Case report and literature review.
    Özdirik B; Jost-Brinkmann F; Savic LJ; Mohr R; Tacke F; Ploner CJ; Roderburg C; Müller T
    Medicine (Baltimore); 2021 Jun; 100(24):e26377. PubMed ID: 34128898
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Life threatening pembrolizumabinduced myositis in a patient treated for advanced adenocarcinoma of the lung.
    Robinson SD; Lai C; Hotton G; Anand G
    Acute Med; 2019; 18(3):197-199. PubMed ID: 31536059
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133).
    Liu SV; Reck M; Mansfield AS; Mok T; Scherpereel A; Reinmuth N; Garassino MC; De Castro Carpeno J; Califano R; Nishio M; Orlandi F; Alatorre-Alexander J; Leal T; Cheng Y; Lee JS; Lam S; McCleland M; Deng Y; Phan S; Horn L
    J Clin Oncol; 2021 Feb; 39(6):619-630. PubMed ID: 33439693
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Myositis induced by durvalumab in a patient with non-small cell lung cancer: A case report.
    Kobayashi M; Saiki M; Omori C; Ide S; Masuda K; Sogami Y; Hata T; Ishihara H
    Thorac Cancer; 2020 Dec; 11(12):3614-3617. PubMed ID: 33103845
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Atezolizumab plus carboplatin and etoposide in small cell lung cancer patients previously treated with platinum-based chemotherapy.
    Ishii H; Azuma K; Kawahara A; Matsuo N; Tokito T; Hoshino T
    Invest New Drugs; 2021 Feb; 39(1):269-271. PubMed ID: 32783090
    [TBL] [Abstract][Full Text] [Related]  

  • 40. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.
    Horn L; Mansfield AS; Szczęsna A; Havel L; Krzakowski M; Hochmair MJ; Huemer F; Losonczy G; Johnson ML; Nishio M; Reck M; Mok T; Lam S; Shames DS; Liu J; Ding B; Lopez-Chavez A; Kabbinavar F; Lin W; Sandler A; Liu SV;
    N Engl J Med; 2018 Dec; 379(23):2220-2229. PubMed ID: 30280641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.